Simple Summary In this review, we describe arginine's role as a signaling metabolite,
epigenetic regulator and mitochondrial modulator in cancer cells, and summarize recent …

Metabolic inhibitors have been used in oncology for decades, dating back to antimetabolites
developed in the 1940s. In the past 25 years, there has been increased recognition of …

The concept that dietary changes could improve the response to cancer therapy is extremely
attractive to many patients, who are highly motivated to take control of at least some aspect …

Osteosarcoma is the most common primary malignant bone tumor in children and young
adults. The standard-of-care curative treatment for osteosarcoma utilizes doxorubicin …

SCLC is an aggressive form of lung cancer with a very poor prognosis. Although SCLC
initially responds very well to platinum-based chemotherapy, it eventually recurs and at …

Abstract Ribonucleotide reductase M2 (RRM2) is a small subunit in ribonucleotide
reductases, which participate in nucleotide metabolism and catalyze the conversion of …

Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies with an
extremely poor prognosis. Energy metabolism reprogramming, an emerging hallmark of …

Leiomyosarcoma is an aggressive mesenchymal malignancy and represents one of the
most common subtypes of soft tissue sarcomas. It is characterized by significant disease …

Osteosarcoma is the most common pediatric and adult primary malignant bone cancer.
Curative regimens target the folate pathway, downstream of serine metabolism, with high …